The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 1994-2005

  Anderson, Ryan T ^a   Keysar, Stephen B ^a   Bowles, Daniel W ^a   Glogowska, Magdalena J ^a   Astling, David P ^a   Morton, J Jason ^a   Le, Phuong ^a   Umpierrez, Adrian ^a   Eagles Soukup, Justin ^a   Gan, Gregory N ^a   Vogler, Brian W ^a   Sehrt, Daniel ^a   Takimoto, Sarah M ^a   Aisner, Dara L ^a   Wilhelm, Francois ^b   Frederick, Barbara A ^a   Varella Garcia, Marileila ^a   Tan, Aik Choon ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Onconova Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE 1; PROTEIN KINASE B; PROTEIN S6; RIGOSERTIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; EXON; GENE AMPLIFICATION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE PRODUCT; GENE SEQUENCE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PIK3CA GENE; PRIORITY JOURNAL; TP53 GENE; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; GLYCINE; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885571008     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0206     Document Type: Article

References (52)

1. Haddad RI, Shin DM. Recent advances in head and neck cancer. New Engl J Med 2008;359: 1143-54.
2. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 2011;10:12.
3. Cardesa A, Nadal A. Carcinoma of the head and neck in the HPV era. Acta Dermatovenerol Alp Panonica Adriat 2011;20: 161-73.
4. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11: 9-22.
5. Kreimer AR, CliffordGM,Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14: 467-75.
6. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29: 4294-301.
7. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004;109: 157-62.
8. Myers EN. Head and neck oncology-2010, part I. Otolaryngol Pol 2010;64: 136-46.
9. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333: 1157-60.
10. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus- associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24: 736-47.
11. Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 2005;24: 7830-8.
12. Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res 2006;66: 5555-9.
13. Charette ST, McCance DJ. The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner. Oncogene 2007;26: 7386-90.
14. Contreras-Paredes A, De la Cruz-Hernandez E, Martinez-Ramirez I, Duenas-Gonzalez A, Lizano M. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology 2009;383: 78-85.
15. Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG, et al. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/ phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clin Cancer Res 2010;16: 5200-10.
16. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333: 1154-7.
17. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T, et al. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002;198: 335-42.
18. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13: 2905-27.
19. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14: 381-95.
20. Estilo CL, O-Charoenrat P, Ngai I, Patel SG, Reddy PG, Dao S, et al. The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res 2003;9: 2300-6.
21. Or YY, Hui AB, Tam KY, Huang DP, Lo KW. Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol 2005;26: 49-56.
22. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010;10: 342-52.
23. Howard JD, Lu B, Chung CH. Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol 2012;48: 10-7.
24. Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, Davies BR, et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 2008;121: 664-74.
25. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998;16: 1671-9.
26. Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010;28: 761-6.
27. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012;18: 290-300.
28. Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012; 18: 1979-91.
29. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7: 275-86.
30. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17: 304-15.
31. Prasad A, Park IW, Allen H, Zhang X, Reddy MV, Boominathan R, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009;28: 1518-28.
32. Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, et al. Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon) and ON013105, for brain tumor chemotherapy. Pharm Res 2012;29: 2499-511.
33. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4: 249-64.
34. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics 2007;23: 3251-3.
35. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314: 268-74.
36. Clague MJ, Urbe S, de Lartigue J. Phosphoinositides and the endocytic pathway. Exp Cell Res 2009;315: 1627-31.
37. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22: 2616-24.
38. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7: 248-9.
39. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11: 2875-8.
40. Reddy MV, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA, et al. Discovery of a clinical stage multikinase inhibitor sodium (E)-2-{2-methoxy-5-[(20,40,60-trimethoxystyrylsulfonyl) methyl]phenylamino} acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem 2011;54: 6254-76.
41. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12: 1441-6.
42. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol 2013;7: 776-90.
43. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009;45: 324-34.
44. Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS ONE 2013;8:e53292.
45. Soeda H, Shimodaira H, Watanabe M, Suzuki T,GamohM, Mori T, et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatinrefractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol. 2012 May 26. [Epub ahead of print].
46. Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Pelletier L, et al. BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: an exploratory analysis. Oncol Lett 2012; 4: 141-5.
47. Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, et al. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res 2012;18: 2048-55.
48. Jimeno A, Bowles D, Aisner D, Diamond J, Lam E, Weekes C, et al. Phase 1 and Molecular Correlates Study of Oral Rigosertib in Patients with Refractory Metastatic Head and Neck Cancer and Advanced Solid Tumors. 104th American Association for Cancer Research (AACR) Annual Meeting, Oral presentation abstr LB-198, April 2013.
49. Hsiao JR, Leu SF, Huang BM. Apoptotic mechanism of paclitaxelinduced cell death in human head and neck tumor cell lines. J Oral Pathol Med 2009;38: 188-97.
50. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16: 984-93.
51. Yarbrough WG, Whigham A, Brown B, Roach M, Slebos R. Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007;69:S98-101.
52. Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG, et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 2011;71: 2706-17.